Ask AI
Back Back
Diagnosing Cancer Cachexia

CE / CME

Signs and Symptoms of Cachexia and Optimizing Diagnostic Tools to Assess, Measure, and Document Cancer Cachexia

Physician Assistants/Physician Associates: 0.25 AAPA Category 1 CME credit

Pharmacists: 0.25 contact hour (0.025 CEUs)

Physicians: maximum of 0.25 AMA PRA Category 1 Credit™

Nurse Practitioners/Nurses: 0.25 Nursing contact hour

European Learners: 0.25 EBAC® CE Credit

Released: March 25, 2026

Expiration: September 24, 2026

Ester Oneda
Ester Oneda, MD
CME/CE Information

Activity

Progress
1 2 3
Course Completed

Cancer Cachexia: Importance of Diagnosis

As previously mentioned, cancer cachexia is clinically important because it is characterized by the loss of skeletal muscle mass, associated with a functional decline, and linked to diminished tolerance to systemic anticancer therapy, increased TRAEs, compromised overall survival, and reduced QoL. Despite these consequences, cachexia is still underrecognized, underdiagnosed, and undertreated in routine oncology practice today.1,9-11

With these challenges in mind, I will delve deeper into the available diagnostic tools that can be used to assess, measure, and accurately document cachexia for our patients with advanced-stage cancer who are receiving treatment. The importance of patient screening for cancer cachexia cannot be overstated.

To achieve optimal treatment outcomes, rapid screening tools such as MST, NRS‑2002, and the modified Glasgow Prognostic Score are readily available, and these tools may be used to help with the identification of patients with advanced cancer and cachexia who can benefit from interventions such as targeted nutritional and/or metabolic interventions with or without individualized exercise or training programs.1,24

Download

Assessment of Cancer Cachexia: Anthropometric and Clinical Measures

Clinical assessment typically begins with simple measures such as the determination of body weight, unintentional weight loss, BMI, and determinations of whether the patient has a reduced food intake or anorexia.1,24-26 If so, the underlying reasons contributing to food intake reduction should be determined. It is also important to determine physical function and body composition, and to assess whether the patient meets specific diagnostic thresholds. The management plan should feature an individualized approach, which can be based on the patient's characteristics at baseline.

For the determination of physical function and muscle strength, upper-limb handgrip dynamometry, 6-minute walk test, and performance status evaluations are approaches that can be utilized. To assess for body composition or muscle mass, options include computed tomography (CT) imaging at the level of the third lumbar vertebra (L3), which provides an accurate and prognostically relevant measure of skeletal muscle mass and is often considered the reference standard for body composition assessment. Dual-energy x-ray imaging or skeletal muscle index quantification can also be considered if CT imaging is not available.

Key diagnostic thresholds to diagnose cachexia include unintentional weight loss >5% within 6 months or ≥2% weight loss in patients who already have a low BMI or evidence of sarcopenia.

Download

Assessment Methods and Diagnosis

Cancer cachexia is a dynamic phenomenon, and patients, particularly those with advanced cancer who are receiving treatment, should be screened for this phenomenon on a longitudinal basis over time.1,27,28 As previously stated, screening should include assessments for weight loss, BMI, muscle mass and strength, and food intake <75% at every visit to the clinic. Assessment measures also include the determination of biomarkers of inflammation.

Diagnosis and staging of cancer cachexia include the determination of the weight loss trajectory and assessments for BMI or sarcopenia. A patient with weight loss >5% within the past 6 months is categorized as having cachexia if the patient has a BMI >20 kg/m². A patient with a BMI <20 kg/m² is classified as having cachexia if the patient has ongoing weight loss >2%. A patient with sarcopenia and ongoing weight loss of >2% is also considered to have cachexia.

Of significant importance, cancer-associated cachexia can impact patients with obesity, and the loss of skeletal muscle mass may occur even when overall body weight appears stable.29 So, it is critical to reiterate that the sole reliance on the determination of body weight trajectory is not sufficient to accurately diagnose cachexia.

The patient, caregiver, and healthcare team need to discuss the goals of care. With cancer cachexia being a multifactorial syndrome, a multimodal treatment approach that includes an individualized combination of nutrition counseling, adapted exercise, appetite stimulants, and symptom control measures is needed. To avoid progression to refractory cachexia, patients require careful monitoring and treatment adjustments throughout the course of treatment.

Download

Emerging Assessment Methods

To achieve optimal outcomes and improve QoL for patients, it is crucial that the signs and symptoms of cancer cachexia are promptly recognized and accurately diagnosed at early onset. Fortunately, newer assessment methods that move beyond single static measurements are emerging.10,30 These methods include the incorporation of digitalized, artificial intelligence–assisted imaging tools, determination of biomarkers of inflammation such as IL-6, CRP, and GDF-15, physical function assessment tests, and digital applications or wearable devices that can more easily be used to assess body composition trajectories. For instance, miniCASCO is a method that incorporates weight trajectories, levels of inflammation biomarkers, nutritional status, functional capacity, and some QoL parameters to diagnose cancer cachexia. These approaches, along with digital devices and applications, can assist HCPs in tracking longitudinal body composition changes and help to identify clinically meaningful signs and symptoms of cachexia earlier in its course.

Download

Clinical Challenge and Management Approach

To date, cancer cachexia remains underdiagnosed in clinical practice in part because routine screening protocols are not consistently implemented, and because there are currently no approved pharmacologic agents, especially in the United States and Europe. Of consequence, diagnosis may be delayed and opportunities for early intervention may be missed. Of note, anamorelin, an oral selective agonist of the ghrelin receptor, is approved in Japan for patients with cancer cachexia.31

Early detection of cancer cachexia allows HCPs to initiate appropriate treatment strategies before irreversible muscle loss occurs.1,10,29 This will fundamentally change the course of the syndrome by preventing substantial weight loss and preserving physical function, which in turn will result in a higher potential for significantly improving the chance of functional independence.

Download

Overcoming Barriers to Diagnosis

Common barriers that can delay the early diagnosis of cancer cachexia include time constraints, lack of ownership of the condition by any segment of the healthcare team, normalization of weight loss when the patient is receiving anticancer therapy, and a fragmented clinical workflow at cancer centers.29

These barriers can be addressed through the institution of systematic screening protocols, the use of a multidisciplinary team collaboration, easier accessibility to the electronic health record, and targeted clinical education for both the patient/caregiver and the healthcare team.

Download
BACK | NEXT